Allergy Immunotherapy denied for failing step therapy by Humana?

Humana's specific coverage criteria for allergy immunotherapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Step Therapy for Allergy Immunotherapy — and How to Appeal

Step therapy (sometimes called "fail-first") policies require patients to try and fail lower-cost or lower-intensity treatments before a plan will cover the requested one. For allergy immunotherapy, Humana may require documented failure of pharmacological management — such as antihistamines, nasal corticosteroids, or other symptom-control medications — before approving an immunotherapy course. When that documentation is missing or the insurer concludes you have not adequately trialed the prerequisite options, coverage is denied.

This denial pattern is common, but it is frequently reversible on appeal — particularly when your allergist can demonstrate that prior therapies were tried and failed, were contraindicated for your specific situation, or that the clinical urgency of your condition makes step therapy medically inappropriate.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): You are entitled to a full-and-fair review. The plan must provide the specific criteria it applied, the documents it relied on, and the clinical rationale for the denial — all in a form you can respond to.
• External review (ACA §2719): If internal appeal fails, you can escalate to an independent IRO. The reviewer applies recognized medical standards, not Humana's internal policies alone. Check your denial letter for the submission window — it is typically around 180 days from the final internal denial.
• Expedited review: Available when a standard timeline could seriously harm your health. Turnaround is typically required within 72 hours.
• State step-therapy protections: Many states have enacted step-therapy reform laws that limit when insurers can require fail-first protocols and create override pathways. Check whether your state has such a law and whether your plan is subject to it (fully-insured state-regulated plans are; self-funded ERISA plans may not be).

## Documentation to Gather

1. Prior therapy records — Pharmacy fill history and clinical notes documenting every allergy medication tried, the dates of use, doses attempted (per your prescriber's records), and the outcomes or adverse effects that led to discontinuation. 2. Diagnosis confirmation — Allergy testing establishing the allergen profile and clinical severity. 3. Physician step-therapy override letter — A letter from your allergist explaining why the step-therapy requirement does not apply: either because the prerequisite steps were completed, or because proceeding to immunotherapy is clinically required without further delay. 4. Applicable guideline organization reference — The allergist should note that relevant professional bodies (e.g., the American Academy of Allergy, Asthma & Immunology) recognize immunotherapy as appropriate when pharmacotherapy is inadequate — without citing specific statistics. 5. Impact on daily functioning — Chart notes describing symptom burden, missed work or school, and quality-of-life impairment that standard medications failed to adequately control.

## Criteria-Mapping Strategy

Obtain Humana's step-therapy policy for allergy immunotherapy. Copy each requirement verbatim. For every requirement, provide the chart-based evidence that satisfies it — or the clinical explanation for why that step was appropriately bypassed. A structured, criterion-by-criterion response is significantly more persuasive than a narrative letter alone and leaves no requirement unanswered.